Observational studyNeurology. Clinical practice2026
Infection Risk During Rituximab Therapy in Multiple Sclerosis: Effect of Dosing Interval and Age.
Observational study in Neurology. Clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesRituximab is the most frequently used disease-modifying therapy in multiple sclerosis (MS) in Norway. Extended dosing intervals beyond 6 months may offer the same efficacy, but the impact on infection risk is unclear. We examined how dosing frequency and age affect infection risk in rituximab-treated patients with MS.
methodsWe conducted a nation-wide observational study linking compulsory Norwegian health registries with the Norwegian MS registry. Registry data captured hospital-treated infections and further infections requiring prescription treatment and/or physician contact with primary practice. Data were analyzed using the Prentice, Williams, and Peterson model with clustering on subject to account for longitudinal design, recurrent rituximab infusions and recurrent infection events while adjusting for relevant explanatory variables. Rituximab interval length was modelled as the number of rituximab infusions within 2 years. Age was grouped into 5-year intervals.
resultsAmong 3,410 patients (13,811 treatment episodes between 2010 and June 2022), 13,774 infections occurred, including 971 hospital-treated events. Compared with 4 infusions over 2 years (6-month intervals), extended dosing was associated with a lower risk of any infection (hazard ratio [HR] 0.90 [95% CI 0.82-0.99]) for 2 infusions; (HR 0.78 [95% CI 0.69-0.88] for 1 infusion). A reduced risk of hospital-treated infections was observed only for 1 infusion per 2 years relative to 4, and this was not robust in sensitivity analyses and not present for the subgroup of infections associated with overnight hospital stay. Patients ≥60 years had a significantly higher risk of hospital-treated infections (HR 1.36 [95% CI 1.07-1.71]). DISCUSSION: Extended rituximab intervals are associated with reduced overall infection risk, but the benefit for hospital-treated infections is limited. Age ≥60 years independently increases the risk of hospital-treated infections. These findings support cautious interval extension and careful risk-benefit assessment in older patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.